Imatinib (Gleevec) belongs to which generation of targeted drugs and analysis of its clinical application

Imatinib (Imatinib, trade name: Gleevec/Gleevec) is the first generation tyrosine kinase inhibitor (TKI), known as "the beginning of targeted therapy". It blocks the abnormal proliferation signaling pathway of leukemia cells by selectively inhibiting the tyrosine kinase activated by the BCR-ABL fusion gene. The advent of imatinib ushered in a new era of tumor treatment and is considered an important milestone in precision medicine.

The core indication of imatinib is Philadelphia chromosome-positive chronic myeloid leukemia (CML), which has significantly improved the long-term survival rate and quality of life of patients. In addition, imatinib is also widely used in acute lymphoblastic leukemia (Ph+ ALL), gastrointestinal stromal tumors (GIST), myelodysplastic syndromes and certain rare solid tumors. These applications have expanded its clinical value, making it an important treatment option for a variety of malignancies.

Clinical studies have shown that imatinib can achieve a complete cytogenetic response rate of CML patients to more than 80%, greatly extending the median survival period of patients, and many patients have achieved long-term survival or even close to normal life span. For GIST patients, imatinib also significantly delayed disease progression and reduced the risk of recurrence. Its emergence makes it possible to "chronicize cancer" and lays the foundation for the subsequent development of second- and third-generation TKI drugs.

Although imatinib has epoch-making clinical significance, some patients will experience reduced efficacy due to drug resistance or adverse reactions. In such cases, second-generation TKIs (such as dasatinib, nilotinib) or third-generation TKIs (such as pomatinib) need to be considered. Overall, imatinib, as a first-generation targeted drug, is still the first-line drug for diseases such as CML. Its safety and efficacy have been widely verified around the world, and it may continue to play an important role in personalized treatment and combination programs in the future.

Reference materials:https://www.drugs.com/